Making Antimicrobial Peptides Last Longer by Closing Them Into Rings to Fight Drug-Resistant Bacteria

By combining cyclization (closing the peptide into a ring) and D-amino acid substitution (using mirror-image amino acids), researchers transformed a linear antimicrobial peptide called P-07 into PT-17 — a dramatically more stable version that resists enzymatic breakdown. PT-17 retained broad-spectrum killing activity against multidrug-resistant (MDR) bacteria, showed a high therapeutic index (meaning it kills bacteria at much lower concentrations than those toxic to human cells), disrupted bacterial membranes rapidly, showed low potential to trigger resistance, and worked synergistically with conventional antibiotics. In mice infected with MDR E. coli, PT-17 significantly reduced bacterial loads in major organs with no detectable toxicity.

Starting from a linear β-turn antimicrobial peptide (P-07), the researchers created multiple cyclized derivatives using disulfide bonds and lactam bonds, plus versions with D-amino acid substitutions. They tested stability against enzymatic degradation, antimicrobial activity against MDR bacteria, membrane disruption speed, resistance development potential, and synergy with existing antibiotics. The lead compound PT-17 was then tested in a mouse infection model using MDR E. coli.

Antibiotic resistance is a global crisis, and antimicrobial peptides (AMPs) represent one of the most promising alternatives to conventional antibiotics. However, natural AMPs are rapidly destroyed by enzymes in the body. This study demonstrates that two stabilization strategies — cyclization and D-amino acid substitution — can be combined to make β-turn AMPs dramatically more stable without sacrificing their ability to kill resistant bacteria. This provides a practical blueprint for turning promising lab peptides into viable drug candidates.

With antibiotic resistance projected to kill 10 million people per year by 2050, antimicrobial peptides are among the most actively explored alternatives. The central challenge has always been stability — the body breaks peptides down too fast. This study solves that problem for an underexplored class of peptides (β-turn AMPs) using a combination strategy that could be broadly applied. The demonstration that PT-17 works synergistically with existing antibiotics is particularly promising, as combination therapy could revive the effectiveness of drugs that bacteria have become resistant to.

This is preclinical research — no human trials have been conducted. The mouse infection model, while informative, may not fully predict clinical performance. Specific MIC values and quantitative organ bacterial load reductions were not detailed in the abstract. Manufacturing scalability and cost of the cyclized peptide are not addressed. Long-term safety data are not available.